Loading clinical trials...
Loading clinical trials...
A Multi-center, Open-label, Uncontrolled, Long-term, Extension Study to Evaluate the Safety and Efficacy of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Partial-onset Seizures With or Without Secondary Generalization
The purpose of this trial is to evaluate the safety and tolerability of long-term administration of Lacosamide at doses up to 400 mg/day in Japanese and Chinese adults with Epilepsy who have completed the Treatment and Transition Period of EP0008 \[NCT01710657\]
Age
16 - 70 years
Sex
ALL
Healthy Volunteers
No
86026
Beijing, China
86027
Beijing, China
86015
Changchun, China
86005
Chengdu, China
86032
Chengdu, China
86006
Chongqing, China
86031
Dalian, China
86007
Guangzhou, China
86008
Guangzhou, China
86009
Guangzhou, China
Start Date
March 26, 2013
Primary Completion Date
July 31, 2019
Completion Date
July 31, 2019
Last Updated
August 17, 2021
473
ACTUAL participants
Lacosamide
DRUG
Lead Sponsor
UCB Pharma SA
Collaborators
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions